Form 4: Spero Therapeutics COO Timothy Keutzer Reports Stock Transactions

Timothy Keutzer, Chief Operating Officer of Spero Therapeutics, reports the acquisition and disposal of common stock related to restricted stock units.

Summary

• On February 3, 2025, Timothy Keutzer acquired 266,139 shares of Spero Therapeutics common stock.
• These shares were acquired through restricted stock units (RSUs) that vest in four equal annual installments beginning February 3, 2026.
• On February 5, 2025, Keutzer sold 3,974 shares at $0.78 per share, 27,643 shares at $0.78 per share, and 24,920 shares at $0.78 per share.
• These sales were to cover tax withholding obligations related to the vesting of RSUs granted on February 1, 2022, February 1, 2023, and February 1, 2024, respectively.
• Following these transactions, Keutzer beneficially owns 741,439 shares of Spero Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and related to executive compensation and tax obligations. There's no indication of unusual activity or concern.

Positives

• The acquisition of shares through RSUs indicates a form of compensation and alignment of interest between the executive and the company's performance.

Negatives

• The sale of shares, even for tax obligations, could be perceived negatively by some investors, although it's a common practice.

Risks

• The value of the stock is subject to market fluctuations, which could impact the value of Keutzer's holdings.
• Future vesting of RSUs is contingent upon continued service with the company.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's confidence in the company's prospects. 'Sell to cover' transactions are a standard practice to manage tax obligations associated with equity compensation.

Comparison to Industry Standards

• Executive compensation packages often include RSUs as a way to align management's interests with those of shareholders.
• The vesting schedule of four equal annual installments is a typical structure for RSUs.
• Selling shares to cover tax obligations is a common practice among executives receiving equity compensation; this is similar to practices at companies like Pfizer, Moderna, and BioNTech where executives routinely manage their equity holdings for tax purposes.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in Keutzer's holdings, but the overall impact is likely minimal.

Key Dates

Keywords

Spero Therapeutics, SPRO, Timothy Keutzer, Form 4, Beneficial Ownership, Restricted Stock Units, RSUs, Stock Sale, Tax Withholding